UOC
AVIR icon

UBS O'Connor’s Atea Pharmaceuticals AVIR Stock Holding History

UBS O'Connor’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-50,000
Closed -$1.75M – 945
2021
Q3 		$1.75M Buy
+50,000
New +$1.39M 0.01% 562

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

UBS O'Connor's AVIR Position: Q4 2021 in Review

UBS O'Connor sold out of Atea Pharmaceuticals (AVIR) in Q4 2021, closing a stake of 50,000 shares — an estimated $1.75M sold.

UBS O'Connor first reported a position in AVIR in Q3 2021 and held it in 1 quarter. The position peaked at $1.75M in Q3 2021. 143 funds tracked by Wall St. Rank hold AVIR as of Q4 2021.

  • UBS O'Connor reported no remaining Atea Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • UBS O'Connor sold 50,000 Atea Pharmaceuticals shares in Q4 2021, an estimated $1.75M.
  • UBS O'Connor first reported a position in Atea Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • UBS O'Connor's Atea Pharmaceuticals position peaked at $1.75M in Q3 2021.
  • 143 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2021.

Based on UBS O'Connor's 13F filing for Q4 2021, filed 14 Feb 2022.